Lp-PLA2: A new target for statin therapy

Current Atherosclerosis Reports

Volumn 12, Issue 1, 2010, Pages 29-33

  Braun, Lynne T ^a   Davidson, Michael H ^b  

^a RUSH UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

CHD risk assessment; Inflammatory markers; Lipoprotein associated phospholipase A2; Lp PLA2

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATORVASTATIN; C REACTIVE PROTEIN; DARAPLADIB; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DYSLIPIDEMIA; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; BLOOD; DRUG EFFECT; ENZYMOLOGY; MORBIDITY; PROGNOSIS; RISK FACTOR; SURVIVAL RATE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKERS; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MORBIDITY; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 77149166009     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-009-0074-y     Document Type: Review

References (21)

1. Ridker PM, Riffai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.
2. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006;145:21-9.
3. 2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006;26:1586-93.
4. 2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol 2008;101(Suppl) :23F-33F.
5. 2 as a cardiovascular risk marker. Am J Cardiol 2008;101(Suppl) :41F-50F.
6. 2: a risk marker or a risk factor? Am J Cardiol 2008;101(Suppl) :11F-22F.
7. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-21.
8. 2.
9. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, et al. Centers for Disease Control and Prevention. American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
10. 2, high-sensitivity C-reactive protein, and risk for incident heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004;109:837-42.
11. 2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005;165:2479-84.
12. 2 and risk of stroke. Am J Cardiol 2008;101(Suppl) :34F-40F.
13. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, et al., for the National Heart, Lung and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
14. Davidson MH. Clinical significance of statin pleiotropic effects. Hypotheses versus evidence. Circulation 2005;111:2280-2281.
15. 2 in patients with coronary heart disease versus control subjects. Am J Cardiol 2005;95:1025-32.
16. Muhlestein JB, May HT, Jensen JR, Horne BD, Lanman RB, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia. The DIACOR (Diabetes and Combined Lipid Therapy Regimen) Study. J Am Coll Cardiol 2006;48:396-401.
17. 2. Arterioscler Thromb Vasc Biol 2007;27:2236-43.
18. Shalwitz RA, Maki KC, Doyle RT, Ballantyne CM. Lipoprotein subfraction responses differentially predict changes in lipoprotein-associated phospholipase A2 during prescription omega-3 therapy. Arterioscler Thromb Vasc Biol 2007;27:e93.
19. 2 activity, as well as interleukin-6 and hs-CRP.
20. Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008;14:1059-66.
21. Serruys PW, García-García HM, Buszman P, Erne P, Verheye S, et al.; Integrated Biomarker and Imaging Study-2 Investigators. Effects of the direct lipoprotein-associated phospholipase A (2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118:1172-82.